Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 3 | $0.02 | $0.02 | $0.02 |
Q2 2025 | 1 | $0.03 | $0.03 | $0.03 |
Q3 2025 | 1 | $0.03 | $0.04 | $0.04 |
Q4 2025 | 1 | $0.05 | $0.05 | $0.05 |
Q1 2026 | 1 | $0.03 | $0.03 | $0.03 |
Q2 2026 | 1 | $0.04 | $0.04 | $0.04 |
Q3 2026 | 1 | $0.05 | $0.05 | $0.05 |
Q4 2026 | 1 | $0.07 | $0.07 | $0.07 |
Q1 2027 | 1 | $0.04 | $0.04 | $0.04 |
Q2 2027 | 1 | $0.05 | $0.05 | $0.05 |
Q3 2027 | 1 | $0.06 | $0.06 | $0.06 |
Q4 2027 | 1 | $0.07 | $0.08 | $0.08 |
Niagen Bioscience Inc last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 29.13 M for the quarter and had revenue of 99.60 M for the year. Niagen Bioscience Inc has generated $0 earnings per share over the last year ($0.11 diluted earnings per share) and currently has a price-to-earnings ratio of 67.23. Niagen Bioscience Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
12/31/2024 | Q4 2024 | N/A | $0.09 | N/A | $26.78 M | $29.13 M |
09/30/2024 | Q3 2024 | N/A | $0.02 | N/A | $24.03 M | $25.58 M |
06/30/2024 | Q2 2024 | N/A | -$0.00 | N/A | $23.33 M | $22.74 M |
03/31/2024 | Q1 2024 | N/A | -$0.01 | N/A | $23.48 M | $22.15 M |
12/31/2023 | Q4 2023 | N/A | $0.00 | N/A | $20.81 M | $21.20 M |
09/30/2023 | Q3 2023 | N/A | -$0.01 | N/A | $20.30 M | $19.50 M |
06/30/2023 | Q2 2023 | N/A | -$0.03 | N/A | $19.42 M | $20.32 M |
03/31/2023 | Q1 2023 | N/A | -$0.03 | N/A | $19.41 M | $22.56 M |
12/31/2022 | Q4 2022 | N/A | -$0.02 | N/A | N/A | $21.00 M |
09/30/2022 | Q3 2022 | N/A | -$0.01 | N/A | N/A | $17.06 M |
06/30/2022 | Q2 2022 | N/A | -$0.09 | N/A | N/A | $16.73 M |
03/31/2022 | Q1 2022 | N/A | -$0.11 | N/A | N/A | $17.26 M |
12/31/2021 | Q4 2021 | N/A | -$0.08 | N/A | N/A | $17.76 M |
09/30/2021 | Q3 2021 | N/A | -$0.13 | N/A | N/A | $17.31 M |
06/30/2021 | Q2 2021 | N/A | -$0.08 | N/A | N/A | $17.70 M |
03/31/2021 | Q1 2021 | N/A | -$0.12 | N/A | N/A | $14.68 M |
12/31/2020 | Q4 2020 | N/A | -$0.10 | N/A | N/A | $15.45 M |
09/30/2020 | Q3 2020 | N/A | -$0.07 | N/A | N/A | $14.18 M |
06/30/2020 | Q2 2020 | N/A | -$0.06 | N/A | N/A | $15.29 M |
03/31/2020 | Q1 2020 | N/A | -$0.10 | N/A | N/A | $14.35 M |
The conference call for Niagen Bioscience Inc's latest earnings report can be listened to online.
The conference call transcript for Niagen Bioscience Inc's latest earnings report can be read online.
Niagen Bioscience Inc (:NAGE) has a recorded annual revenue of $99.60 M.
Niagen Bioscience Inc (:NAGE) has a recorded net income of $8.55 M.Niagen Bioscience Inc has generated $0.1 earnings per share over the last four quarters.
Niagen Bioscience Inc (:NAGE) has a price-to-earnings ratio of 67.23 and price/earnings-to-growth ratio is 0.11.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED